From January 1, 2024, Ashley Magargee’s role as chief executive of the Roche (ROG: SIX) subsidiary Genentech will become permanent.
In addition to her role as head of US commercial portfolio, Ms Magargee has been serving as ad interim chief executive since the departure of Alexander Hardy last month.
"Ashley is a Roche and Genentech veteran"She will report to Teresa Graham, chief executive of Roche Pharma, and become a member of the Pharma leadership team.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze